News
Should You Buy, Sell or Hold IAMGOLD Ahead of Q4 Earnings?
IAMGOLD Corporation IAG is slated to report fourth-quarter 2025 results after market close on Feb. 17. The company’s performance is expected to have benefited from strong production growth and
Lyft Earnings & Revenues Fall Short of Estimates in Q4, Decrease Y/Y
Lyft, Inc. LYFT reported unimpressive fourth-quarter 2025 results, wherein both earnings and revenues missed the Zacks Consensus Estimate.
Lyft reported loss per share of 20 cents compared with the
Toll Brothers to Report Q1 Earnings: Here's What Investors Must Expect
Toll Brothers, Inc. TOL is scheduled to report its first-quarter fiscal 2026 results on Feb. 17, after market close.In the last reported quarter, the company’s adjusted earnings missed the Zacks
MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell?
Merck’s MRK stock has risen 7.4% in the past month. A key driver of the increase was better-than-expected fourth-quarter results and a more confident outlook for its future growth.
In the fourth
Is RIO's Higher Copper Production a Catalyst for Future Growth?
Rio Tinto Group RIO reported solid growth in iron ore production in the fourth quarter of 2025. Per the production results, the company’s consolidated copper output increased 5% year over year in
Hecla Mining Q4 Earnings on the Deck: How to Approach the Stock Now?
Hecla Mining Company HL is scheduled to release fourth-quarter 2025 results on Feb. 17, after market close. The Zacks Consensus Estimate for earnings is currently pegged at 14 cents per share on
How to Approach Harley-Davidson Stock After Q4 Earnings Release?
Harley-Davidson, Inc. HOG, one of the leading motorcycle makers in the world, reported a loss of $2.44 per share in fourth-quarter 2025, wider than a loss of 93 cents per share in the year-ago
Molson Coors' Q4 Earnings Upcoming: What Investors Need to Know?
Molson Coors Beverage Company TAP is expected to register top and bottom-line declines when it reports fourth-quarter 2025 earnings on Feb. 18, after market close. The Zacks Consensus Estimate for
Advance Auto Q4 Earnings Beat Expectations, Revenues Decline Y/Y
Advance Auto Parts, Inc. AAP reported adjusted earnings of 86 cents per share for the fourth quarter of 2025, beating the Zacks Consensus Estimate of 41 cents. The company incurred an adjusted loss
When Love Drives Spending: 5 Stock Picks for Valentine's Day
Valentine’s Day may be about romance, but it’s also a major moment for consumer spending. According to a survey by the National Retail Federation, U.S. consumer spending is expected to hit a record
Twilo's Q4 Earnings Surpass Expectations, Revenues Rise Y/Y
Twilio Inc. TWLO reported better-than-expected fourth-quarter 2025 results, wherein both top and bottom lines surpassed the Zacks Consensus Estimate. The company’s fourth-quarter non-GAAP earnings
Public Storage Beats Q4 FFO & Revenue Estimates, Unveils Initiatives
Public Storage PSA reported fourth-quarter 2025 core funds from operations (FFO) per share of $4.26, which surpassed the Zacks Consensus Estimate of $4.21. The figure increased 1.2% year over
Coinbase Q4 Earnings & Revenues Miss Estimates on Higher Expenses
Coinbase Global, Inc. COIN reported fourth-quarter 2025 net operating earnings per share of 66 cents, which missed the Zacks Consensus Estimate by 28.2%. The bottom line declined 80.4% year over
Near-Perfect CPI Report Brings Pre-Markets Near Breakeven
Friday, February 13th, 2026As far as economic reports go, the good news just keeps on coming. Seemingly running on a separate track from investor fears about AI’s future role in the economy, today’s
Palo Alto Networks to Report Q2 Earnings: How to Play the Stock
Palo Alto Networks, Inc. PANW is scheduled to report its second-quarter fiscal 2026 results on Feb. 17.
Palo Alto Networks projects its fiscal second-quarter revenues in the range of $2.57-$2.59
What Fueled KEY's NII Expansion in 2025 Despite Easing Rates
KeyCorp’s KEY net interest income (NII) (on a tax-equivalent or TE basis) increased 23% year over year to $4.67 billion in 2025. The growth was fueled by strong commercial loan expansion, improved
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss
Agios Pharmaceuticals AGIO reported a loss of $1.85 per share in the fourth quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.97. In the year-ago quarter, the company had
ABM Banks on Multi-Year Strategic Plan ELEVATE Amid Macroeconomic Risk
ABM Industries’ ABM top line is gaining from its multi-year comprehensive strategic plan, ELEVATE, enhancing transparency and efficiency. Rising AI investments through acquisitions are expanding its
Technological Investments & Acquisitions Aid Aptiv Amid Low Liquidity
Aptiv Plc’s APTV top line benefits from its selected acquisitions and strategic investments to leverage growing electrification, connectivity and autonomy trends in the rapidly evolving automotive
PacBio Q4 Earnings and Revenues Beat Estimates, Gross Margin Up
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 12 cents in fourth-quarter 2025, narrower than the year-ago adjusted loss of 20 cents
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
Ultragenyx Pharmaceutical RARE reported fourth-quarter 2025 loss of $1.29 per share, wider than the Zacks Consensus Estimate of a loss of $1.20. The company had incurred a loss of $1.39 per share in
Alliant Energy to Post Q4 Earnings: What to Expect From the Stock?
Alliant Energy LNT is scheduled to release fourth-quarter 2025 results on Feb. 19, after market close. The company delivered a negative earnings surprise of 4.27% in the last reported quarter.Let’s
Penske Q4 Earnings Miss Expectations, Dividend Raised
Penske Automotive Group PAG reported fourth-quarter 2025 adjusted earnings of $2.91 per share, which decreased 17.8% year over year and missed the Zacks Consensus Estimate of $3.19. The company
Here's Why Boot Barn's Store Expansion Strategy Looks Compelling
Boot Barn Holdings, Inc. BOOT continues to generate strong results from its new store engine, consistently surpassing expectations for sales, earnings, and payback across all U.S. regions. This
NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia
Novartis NVS announced positive results from the late-stage III ALIGN study on kidney disease drug Vanrafia (atrasentan).
The ALIGN study is a global, randomized, multicenter, double-blind


